Switching to Subcutaneous (SC) Atezolizumab After Intravenous (IV) Dosing: Evaluation of Atezolizumab Pharmacokinetics (PK) Using Population PK Modeling

被引：0
|
作者：
Liu, Stephanie N. [1 ]
Chan, Phyllis [1 ]
Marchand, Mathilde [2 ]
Herraez-Baranda, Luis [3 ]
Bruno, Rene [4 ]
Chanu, Pascal [5 ]
Wu, Benjamin [1 ]
机构：
[1] Genentech Inc, San Francisco, CA USA
[2] Certara Strateg Consulting, Paris, France
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
[4] Genentech Roche, Marseille, France
[5] Genentech Roche, Lyon, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP01.99
引用
收藏
页码：E44 / E44
页数：1
相关论文
共 42 条
  • [21] Evaluation of brain pharmacokinetics (PK) and tumor growth inhibition of PARP inhibitors in mouse xenograft models using semi-mechanistic PK/pharmacodynamic (PD) modeling
    Liao, Michelle
    Jin, Feng
    Minh Nguyen
    Robillard, Liliane
    Simmons, Andrew D.
    Harding, Thomas C.
    Xiao, Jim J.
    CANCER RESEARCH, 2020, 80 (16)
  • [22] Final Results of the BP22333 Study Demonstrate Non-Inferior Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Administration of Rituximab Compared with Intravenous (IV) Administration As Maintenance Therapy in Patients with Follicular Lymphoma (FL)
    Salar, Antonio
    Avivi, Irit
    Larouche, Jean-Francois
    Janikova, Andrea
    Pereira, Juliana
    Brewster, Mike
    Catalani, Olivier
    McIntyre, Christine
    Sayyed, Pakeeza
    Haynes, Andrew
    BLOOD, 2012, 120 (21)
  • [23] Pharmacokinetics, Lymph Node Uptake, and Mechanistic PK Model of Near-Infrared Dye-Labeled Bevacizumab After IV and SC Administration in Mice
    Wu, Fang
    Tamhane, Mitalee
    Morris, Marilyn E.
    AAPS JOURNAL, 2012, 14 (02): : 252 - 261
  • [24] Pharmacokinetics, Lymph Node Uptake, and Mechanistic PK Model of Near-Infrared Dye-Labeled Bevacizumab After IV and SC Administration in Mice
    Fang Wu
    Mitalee Tamhane
    Marilyn E. Morris
    The AAPS Journal, 2012, 14 : 252 - 261
  • [25] POPULATION PHARMACOKINETIC (PK) MODELING AND SIMULATION OF VARIOUS DOSING INTERVALS AND DETERMINATION OF THE DOSE ADJUSTMENT FACTOR AFTER SC ADMINISTRATION OF IMMUNOGLOBULIN 20% (SCIG 20%) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD)
    Dumas, Todd
    Wolfsegger, Martin
    Berry, N. Seth
    McCoy, Barbara
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2017, 37 (02) : 205 - 206
  • [26] Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T.
    George, Saby
    Bourlon, Maria Teresa
    Chacon, Matias Rodrigo
    Cutuli, Hernan
    Chuken, Yamil Alonso Lopez
    Zurawski, Bogdan
    Mota, Jose Mauricio
    Magri, Ignacio
    Burotto, Mauricio
    Luz, Murilo
    De Menezes, Juliana
    Ruiz, Eduardo Patricio Yanez
    Maruzzo, Marco
    Bracarda, Sergio
    Prusty, Subhransu
    Rathod, Dhanrajsinh
    Vezina, Heather
    Yu, Zhuoxin
    Zhao, Yue
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : LBA360 - LBA360
  • [27] PHARMACOKINETICS (PK) OF CIPROFLOXACIN (CIP) IN ELDERLY PATIENTS (PT) WITH LOWER RESPIRATORY-TRACT INFECTIONS (LRTI) AT STEADY-STATE AFTER INTRAVENOUS(IV) AND ORAL (PO) ADMINISTRATION
    GUAY, DRP
    HIRATA, CA
    STEIN, DJ
    AWNI, WM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (02) : 162 - 162
  • [28] FVIIa-CTP, a novel long acting FVIIa, comprehensive pharmacokinetics and pharmacodynamics and bioavailability evaluation following subcutaneous (SC) and intravenous (IV) administration to hemophilic animal models
    Binder, Lior
    Hoffman, Malka
    Bar-Ilan, Ahuva
    Hart, Gili
    HAEMOPHILIA, 2016, 22 : 78 - 78
  • [29] Calculating iv busulfan (ivBu) dose using body surface area predicts measured drug exposure more accurately than dosing in mg/kg but does not eliminate the need for pharmacokinetics (PK) to obtain dosing precision
    Nance, AG
    Vaughan, WP
    Wang, W
    Salzman, DE
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 32 - 32
  • [30] STEADY-STATE ADALIMUMAB (HUMIRA™) PHARMACOKINETICS (PK) FOLLOWING EVERY OTHER WEEK (EOW) DOSING OF 40mg SUBCUTANEOUS (SC) INJECTION, IN RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH AND WITHOUT CONCOMITANT METHOTREXATE (MTX)
    Awni, W. M.
    Cascella, P.
    Oleka, N.
    Velagapudi, R. B.
    Kupper, H.
    Chartash, E.
    Granneman, R.
    Segurado, O. G.
    Toward, T. J.
    RHEUMATOLOGY, 2004, 43 : 40 - 40
12345